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Gastrointestinalstromaltumors (GIST-)account forthemajorityofmesenchymal tumors arisingwithinthe gastrointestinaltract.
GIST presenting as a palpable abdominal mass is extremely rare. We report four additional cases of a GIST presenting as an
abdominal mass along with a pertinent review of the literature. Twenty ﬁve cases of GISTs presenting with an abdominal mass,
including4 cases discussed here, have been reported in the world literature since 2001.The mean duration of symptoms was 152.7
days. Twenty one of 25 (84%) patients received surgical resection. The mean tumor size was 17.2cm, with an average mitotic
index of 7.6 per 50 high power ﬁelds. Thirteen of 14 (92.9%) patients had a high-risk tumor. Five patients were disease-free at a
mean followup of 11 months, 2 patients had stable disease and 2 patients had progressive disease, and one patient had a partial
response. In conclusion, symptomatic patents have an increased incidence of high-risk tumors and metastases at presentation.
Adjuvant therapy with imatinib improves disease-free survival in patients with large abdominal GIST tumors, but no change in
overall survival was noted. Finally, GISTs should be considered in the diﬀerential diagnosis of an abdominal mass in an elderly
patient.
1.Introduction
Gastrointestinal stromal tumors (GISTs) are the most com-
mon mesenchymal tumors of the gastrointestinal tract.
Terminology used to describe gastrointestinal mesenchymal
tumors has been variable. Traditionally, these tumors have
been called leiomyomas, cellular leiomyomas, or leiomyosar-
comas, depending on the degree of cellularity, mitotic activ-
ity, and evidence of dissemination, or leiomyoblastomas,
when showing epithelioid morphology. Although the term
gastrointestinal stromal tumor is now preferred, phenotypic
overlap between leiomyomas and GISTs exists, especially in
that many GISTs show α-smooth muscle actin expression
and some show desmin expression [1]. The incidence of
GISTs has been historically underestimated prior to the
introduction of CD117 staining. The annual worldwide
incidence of GISTs since introduction of CD117 staining
increased from 1.1 per 100,000 people to 2.1 per 100,000
people. Commensurate with an increased overall incidence
has been a 25-fold increase in the age-adjusted incidence of
GISTs (from 0.028 per 100,000 in 1992 to 0.688 per 100,000
in 2002), with a current annual incidence of 14.5/100,000
population [2]. Most patients with GISTs are asymptomatic
although patients with advanced disease may present with
symptoms of a mass lesion, abdominal pain, or bleeding. At
least 10 to 30% of GISTs are discovered incidentally during
laparotomy, endoscopy, or other imaging studies, with 15%
to50%ofGISTspresentingwithmetastaticdisease[3].GISTs
initially presenting as an abdominal mass are exceedingly
rare, and only 21 such cases have been reported in the world
literature (Table 1). In this paper, we discuss four additional
cases of GISTs presenting as an abdominal mass admitted
at a tertiary care teaching hospital in New Delhi, India and
provide a pertinent review of literature.2 ISRN Surgery
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2.CaseReports
2.1. Case 1. A 60-year male presented with a ﬁve-month
history of an increasing lower abdominal mass with occa-
sional pain. He denied nausea, vomiting, weight loss, or
change in bowel habits. Physical examination revealed a
ﬁxed, mass occupying the right lumbar and iliac fossa.
Contrast-enhanced computed tomography (CECT) scan of
theabdomenandpelvisidentiﬁeda25×15cmlargenecrotic
mass arising from the small intestine with a 1cm hypo-
dense liver lesion. The patient underwent an exploratory
laparotomy andresection ofthetumorand involvedsegment
of the ileum. No evidence of lymph node or peritoneal
metastasis was noted. The histopathological examination of
the resected tumorrevealed a GISTtumorwith free margins.
The mitotic index was 5/50 high-power ﬁelds (HPFs). The
cells showed consistent intracytoplasmic immunoreactivity
for CD117 and CD34. The patient was treated with adjuvant
imatinib therapy.Atoneyearofthefollowup,thepatienthad
no evidence of additional metastatic disease, and the liver
metastasis had shrunk to 0.5cm.
2.2. Case 2. A 45-year female presented with a three-month
history of a progressively enlarging mass in the epigastrium
associated with pain and constipation. She denied nausea,
vomiting, or weight loss. Physical examination revealed a
mobile mass in the periumbilical region partly extending
into epigastrium and the right lumbar region. A contrast-
enhanced CT scan oftheabdomen and pelvis revealeda 15 ×
10cm cystic mass arising from the mesentery of the small
bowel. The patient underwent an exploratory laparotomy
and was found to have a cystic mass arising from the greater
curvature of the stomach. A subtotal gastrectomy with
Billroth II gastrojejunostomy was performed. Histopathol-
ogy of the resected specimen identiﬁed a malignant GIST
tumor with negative surgical margins and no lymph node
involvement. The mitotic index was 7/50 HPF. The cells
showed consistent intracytoplasmic immunoreactivity for
CD117 and CD34. The patient received adjuvant imatinib
therapy and was disease-free at 1-year followup.
2.3. Case 3. A 60-year male presented with a 10-month
history of an asymptomatic increasing upper abdominal
mass. Physical examination revealed a well-deﬁned mobile
hard massin theepigastrium extendingtothelefthypochon-
drium and umbilical region. Contrast-enhanced CT scan
of the abdomen and pelvis identiﬁed a 30 × 10cm mass
arising from the greater curvature of the stomach with
no evidence of metastasis. Esophagogastroduodenoscopy
(EGD) revealed no mucosal lesions. At laparotomy, the
patient was found to have a tumor arising from the posterior
wall of the stomach which was adherent to the spleen
and pancreas. An enbloc subtotal gastrectomy, splenectomy,
and distal pancreatectomy were performed. Histopathology
revealed a GIST tumor with negative surgical margins. The
mitotic index was 9/50 HPF. The cells showed consistent
intracytoplasmic immunoreactivity for CD117 and CD34.
The patient received adjuvant imatinib therapy and was
disease-free at 9-month followup.
2.4. Case 4. A 72-year female presented with a 7-month
history of a slowly increasing mass in the lower abdomen.
She denied nausea, vomiting, weight loss,or change in bowel
habits. Physical examination revealed a well-deﬁned, ﬁrm,
mobile mass occupying the umbilical, hypogastric, and right
iliac fossa. The CA-125tumor marker was normal. Contrast-
enhanced CT scan of the abdomen and pelvis identiﬁed a
25 × 20cm lobulated, heterogeneous soft tissue mass with
areas of hemorrhage and necrosis. There was no evidence
of metastases. The source of the tumor was unclear though
a retroperitoneal sarcoma or ovarian carcinoma seemed
likely. At laparotomy, a 20cm mass was identiﬁed arising
from the gastrocolic ligament and the hepatic ﬂexure of the
transverse colon. A right hemicolectomy with ileo transverse
anastomosis was performed. Histopathologyrevealeda GIST
tumor with negative surgical margins. The mitotic index
was 6/50 HPF. The cells showed consistent intracytoplas-
mic immunoreactivity for CD117 and CD34. The patient
received adjuvant imatinib therapy and remained disease-
free at 1-year followup.
3.Materialsand Methods
A comprehensive English and non-English search for all
articles pertinent to GISTs was conducted for the period
of 2001 and 2009 using PubMed, a search engine provided
by the U.S. National Library of Medicine and the National
Institutes of Health. Key words searched included: gastroin-
testinal stromal tumors, GISTs, and abdominal mass. Cases
identiﬁed were analyzed according to age and gender of the
patients, duration of symptoms, preoperative investigations
and diagnosis, tumor size, number of mitotic ﬁgures,
treatment, and patient outcome. Tumors were classiﬁed as
very low-, low-, moderate-, and high-risk tumors based
on criteria established by Miettinen and Lasota (Table 2)
[24]. The response to the therapy was assessed by using the
modiﬁed computedtomographyresponse evaluationcriteria
[25]. Data was tabulated, and calculations were performed
using Microsoft Excel statistical functions. Statistical analysis
included a mean and median tumor size and a number
of mitotic ﬁgures, and Pearson’s coeﬃcient was used to
determine the correlation between tumor size and mitotic
index.
4.Results
Twenty-ﬁve cases of GISTs presenting with abdominal mass,
including 4 cases discussed here, have been reported in the
world literature since 2001. The mean age was 51.2 (17–83)
years with an M:F ratio of 1:2.1. The mean duration of
symptoms was 152.7days(1–1440days).Allpatients(100%)
had abdominal pain or abdominal mass at presentation.
Contrast-enhanced computer tomography (CECT) was the
most commonlyused modalityofinvestigation. Preoperative
biopsy was done in ﬁve patients and ﬁne needle aspiration
cytology(FNAC)in two patients. Eight of25 patients (4with
biopsy,1withFNAC,and3basedonCECTapprearance)had
a preoperative diagnosis of GIST, which was conﬁrmed by
the histopathology of the resected specimen. In one patient,ISRN Surgery 5
Table 2: Risk stratiﬁcation of primary gastrointestinal stromal tumors for aggressive behavior based on tumor size, site, and mitotic index
[24].
Tumor parameters Risk for progressive disease (%), based on site of origin
Mitotic rate Size Stomach Jejunum/Ileum Duodenum Rectum
≤5p e r5 0H P F
≤2cm None (0%) None (0%) None (0%) None (0%)
>2, ≤5cm Very low (1.9%) Low (4.3%) Low (8.3%) Low (8.5%)
>5, ≤10cm Low (3.6%) Moderate (24%) Insuﬃcient data Insuﬃcient data
>10cm Moderate (10%) High (52%) High (34%) High (57%)
>5p e r5 0H P F
≤2c m N o n e H i g h I n s u ﬃcient data High (54%)
>2, ≤5cm Moderate (16%) High (73%) High (50%) High (52%)
>5, ≤10cm High (55%) High (85%) Insuﬃcient data Insuﬃcient data
>10cm High (86%) High (90%) High (86%) High (71%)
HPF: high-power ﬁeld.
the biopsy was reported as a leiomyosarcoma. Twenty one
of 25 (84%) patients had surgical resection of the tumor, 2
of 25 (8%) patients had an unresectable tumor, one patient
refused treatment, and treatment details were not available
for additional one patient. The stomach was involved in 9
cases, the small bowel in 8 cases, mesentery in 4 cases, and
pancreas and transverse colon in one case each. Primary
site of the tumor was not mentioned in two cases. The
meantumorsize was 17.2(4.5–30)cm,and the mitoticindex
was mentioned in only 14 patients, with an average mitotic
index of 7.6 (2–13) per 50 high-power ﬁelds. Thirteen
of 14 (92.9%) assessable patients had a high-risk tumor,
and one patient had a low-risk tumor. Five of 25 (20%)
patients had metastases and the most common sites of
metastases being peritoneum followed by lymph node and
liver. Twelve patients received adjuvant imatinib therapy
(Glevac), including two patients with an inoperable tumor.
Followup was available for only 2 of 9 patients who had
surgery alone. One patient was disease-free at 6 months, and
another had stable disease at 6 months. Among patients who
received imatinib (N = 12), ﬁve patients were disease-free
at a mean followup of 11 (9–12) months, stable disease or
progressive disease was observed in two patients each, one
patienthad partial response, and response totherapywas not
mentioned in two patients.
5.Discussion
GISTs can occur at any age although they are more common
in adults with a peak incidence in the ﬁfth and sixth decades
oflife.Approximately70%ofGISTsoccurin thestomach, 20
to 30% in the small intestine, and nearly 10% in other parts
of gastrointestinal tract, omentum, or mesentry. The exact
cell of origin and precise steps in tumorogenesis are not well
established however, it appears that these tumors are derived
from the interstitial cell of Cajal. Loss of heterozygosity of
the NF1 gene and mutation in the proto-oncogene c-kit
leading to increased expression of KIT (type III tyrosine
kinase receptor) and platelet-derived growthfactor receptor-
alpha (PDGFRA) are thought to be pivotal [26]. The wild-
type KIT receptors appear to signal through the MAP kinase
pathway [27] as compared to PI3K-AKT cascade used by
KIT mutations associated with sporadic GISTs [28]. The
later ﬁnding may explain the variable response of GISTs to
imatinib therapy.
Microscopically GISTs are classiﬁed into: spindle cell
type (70%), epitheloid type (20%), and mixed spindle cell
and epithelioidcell type. On immunohistochemical staining,
95% are CD117 (c-kit) positive, 70% are CD34, and 40% are
stain positive for smooth muscle actin. GISTs spread by the
hematogenousroute with the liverand peritoneumbeing the
most common sites of metastasis. Rarely, metastases occur to
the lung, bones, and lymph nodes.
A preoperative diagnosis of gastrointestinal stromal
tumor (GIST) is diﬃcult given the nonspeciﬁc signs and
symptoms. Abdominal pain and GI bleeding are the most
common presenting complaints. Patients in whom a GIST
presents as an abdominal mass are exceedingly rare, and
only 25 cases (including 4 cases discussed here) have been
reported (Table 1). The 4 cases presented here mimicked
other surgical conditions like cecal tumor, mesenteric cyst,
stomach carcinoma, ovarian carcinoma, and retroperitoneal
tumor both clinically and radiologically. Contrast-enhanced
CT scan is the imaging modality of choice for patients with
suspected abdominal mass, as it helps in both preoperative
staging and to evaluate for metastatic disease. There are no
speciﬁc CT ﬁndings for GIST tumors although they typically
appear as an inhomogeneous mass with areas of necrosis and
hemorrhage (usually in the center), while viable tumor areas
show contrast enhancement (usually at the periphery) [29].
Liver metastasis typically appears as hypodense area, though
at times they may have a hyperdense rim. Preoperative
biopsy carries a risk of hemorrhage due to the friable
nature of these tumors, and hence it is generally avoided
if deﬁnitive surgery is planned. A ﬁne-needle aspiration
may provide adequate tissue to exclude other malignancies
and, combined with immunohistochemistry and reverse-
transcriptase polymerase chain reaction analysis for KIT
mutations, will generally conﬁrm the diagnosis of GIST if
a biopsy is necessary [30]. Positron emission tomography
(PET) scan is generally not used in the evaluation of GISTs
althoughitishelpfulin theearly detectionoftumorresponse6 ISRN Surgery
to imatinib therapy and in assessing equivocal metastatic
lesions.
Complete surgical resection is the treatment of choice,
and biological therapy (imatinib) is recommended for
incomplete resection and unresectable or metastatic disease
in patients with primary or recurrent disease. In adult
patients with a complete (R0) resection, the FDA has
approved adjuvant therapy with imatinib for tumors with
KIT-positive mutations. Interim results in such patients
have shown that imatinib therapy has increased recurrence-
free survival for moderate-to-high-risk tumors (tumor size
>6cm),withoutan improvement inthe overallsurvival [31].
Radiationtherapyand chemotherapyhaveaverylimitedrole
in the management of GISTs outside of clinical trials.
Tumorsize andmitoticindexarethetwomost important
prognostic factors used for risk stratiﬁcation of GIST
(Table 2). Additional factors such as anatomic location,
histologic variant, and type of mutations have also been
associated with varying prognoses and diﬀerences in overall
survival rates [32]. In this paper, we did not identify a
deﬁnitive correlation between tumor size and mitotic index
(r =− 0.2). Further, the tumor size and mitotic index did
n o tp r e d i c tt h eb e h a v i o ro ft h eG I S T sf o rt h i sg r o u p .T h e s e
ﬁndings indicate that other factors such as type of mutation
may have primary inﬂuence on the aggressive behavior of
GISTs. Finally, Mussi et al. have reported that symptomatic
patients have an increased incidence of intermediate- and
h i g h - r i s kt u m o r sa sw e l la sm e t a s t a s i sa tp r e s e n t a t i o n[ 33].
In a review of 28 patients with GISTs, they found that
63% of patients were symptomatic and 28.5%, 39%, and
18% of patients had intermediate- and high-risk tumors and
metastases, respectively. All patients (100%) discussed here
were symptomatic, and the mitotic index was known in 14
patients of whom 7.1%, 85.7%, and 26.3% of patients had
low- and high-risk tumors and metastases, respectively.
6.Conclusion
Gastrointestinal stromal tumors are highly aggressive
tumors, with uncertain etiology. Other than tumor size
and mitotic index, additional factors such as the anatomic
site, histologic variant, and type of mutation may inﬂuence
the outcome. There appears to be no correlation between
tumor size and mitotic index. Symptomatic patents are
noted to have a higher incidence of high-risk tumors and
metastases at presentation. Adjuvant therapy with imatinib
forpatientswithintermediate- andhigh-risk tumorswith R0
resection improves disease-free survival with no eﬀecton the
overall survival. Finally, GISTs should be considered in the
diﬀerentialdiagnosisofanabdominalmass inadultpatients.
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